ID: ALA2332751

Max Phase: Preclinical

Molecular Formula: C23H21Cl2N3O5

Molecular Weight: 490.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)ccc1-c1cn(C)c(=O)n(C)c1=O

Standard InChI:  InChI=1S/C23H21Cl2N3O5/c1-12-9-13(7-8-14(12)15-11-27(2)23(33)28(3)21(15)30)10-18(22(31)32)26-20(29)19-16(24)5-4-6-17(19)25/h4-9,11,18H,10H2,1-3H3,(H,26,29)(H,31,32)/t18-/m0/s1

Standard InChI Key:  XYXZMKHLXJARTF-SFHVURJKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 490.34

Molecular Weight (Monoisotopic): 489.0858

AlogP: 2.79

#Rotatable Bonds: 6

Polar Surface Area: 110.40

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.54

CX Basic pKa:

CX LogP: 3.76

CX LogD: 0.40

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.55

Np Likeness Score: -0.68

References

1. Sidduri A, Tilley JW, Lou J, Tare N, Cavallo G, Frank K, Pamidimukkala A, Choi DS, Gerber L, Railkar A, Renzetti L..  (2013)  Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.,  23  (4): [PMID:23312474] [10.1016/j.bmcl.2012.12.026]

Source

Source(1):

• Scientific Literature